Search

Your search keyword '"Pass, Martin"' showing total 30 results
Start Over Author "Pass, Martin" Publication Year Range Last 3 years
30 results on '"Pass, Martin"'

1. Identification of Novel, Selective Ataxia-Telangiectasia Mutated Kinase Inhibitors with the Ability to Penetrate the Blood–Brain Barrier: The Discovery of AZD1390

Author

Pike, Kurt G., primary, Hunt, Thomas A., additional, Barlaam, Bernard, additional, Benstead, David, additional, Cadogan, Elaine, additional, Chen, Kan, additional, Cook, Calum R., additional, Colclough, Nicola, additional, Deng, Chao, additional, Durant, Stephen T., additional, Eatherton, Andrew, additional, Goldberg, Kristin, additional, Johnström, Peter, additional, Liu, Libin, additional, Liu, Zhaoqun, additional, Nissink, J. Willem M., additional, Pang, Chengling, additional, Pass, Martin, additional, Robb, Graeme R., additional, Roberts, Caroline, additional, Schou, Magnus, additional, Steward, Oliver, additional, Sykes, Andy, additional, Yan, Yumei, additional, Zhai, Baochang, additional, and Zheng, Li, additional

Published
2024
Full Text
View/download PDF

2. Video 1 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

3. Video 4 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

4. Data from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

5. Supplemenary Figure 2 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Tables 1 through 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure Legends 1-5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

9. Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

11. Data from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

12. Supplementary methods from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Information from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

14. Video 2 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

16. Video 3 - ATMi increases the rate of mitotic catastrophe in glioma cells when p53 is knocked down. from Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Author

Karlin, Jeremy, primary, Allen, Jasmine, primary, Ahmad, Syed F., primary, Hughes, Gareth, primary, Sheridan, Victoria, primary, Odedra, Rajesh, primary, Farrington, Paul, primary, Cadogan, Elaine B., primary, Riches, Lucy C., primary, Garcia-Trinidad, Antonio, primary, Thomason, Andrew G., primary, Patel, Bhavika, primary, Vincent, Jennifer, primary, Lau, Alan, primary, Pike, Kurt G., primary, Hunt, Thomas A., primary, Sule, Amrita, primary, Valerie, Nicholas C.K., primary, Biddlestone-Thorpe, Laura, primary, Kahn, Jenna, primary, Beckta, Jason M., primary, Mukhopadhyay, Nitai, primary, Barlaam, Bernard, primary, Degorce, Sebastien L., primary, Kettle, Jason, primary, Colclough, Nicola, primary, Wilson, Joanne, primary, Smith, Aaron, primary, Barrett, Ian P., primary, Zheng, Li, primary, Zhang, Tianwei, primary, Wang, Yingchun, primary, Chen, Kan, primary, Pass, Martin, primary, Durant, Stephen T., primary, and Valerie, Kristoffer, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 3 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure 5 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

19. Supplementary figure 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure 4 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background

Author

Davies, Barry R., primary, Greenwood, Hannah, primary, Dudley, Phillippa, primary, Crafter, Claire, primary, Yu, De-Hua, primary, Zhang, Jingchuan, primary, Li, Jing, primary, Gao, Beirong, primary, Ji, Qunsheng, primary, Maynard, Juliana, primary, Ricketts, Sally-Ann, primary, Cross, Darren, primary, Cosulich, Sabina, primary, Chresta, Christine C., primary, Page, Ken, primary, Yates, James, primary, Lane, Clare, primary, Watson, Rebecca, primary, Luke, Richard, primary, Ogilvie, Donald, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

21. Supplementary figure 3 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Author

Guichard, Sylvie M., primary, Curwen, Jon, primary, Bihani, Teeru, primary, D'Cruz, Celina M., primary, Yates, James W.T., primary, Grondine, Michael, primary, Howard, Zoe, primary, Davies, Barry R., primary, Bigley, Graham, primary, Klinowska, Teresa, primary, Pike, Kurt G., primary, Pass, Martin, primary, Chresta, Christine M., primary, Polanska, Urszula M., primary, McEwen, Robert, primary, Delpuech, Oona, primary, Green, Stephen, primary, and Cosulich, Sabina C., primary

Published
2023
Full Text
View/download PDF

22. Supplementary Data from Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., primary, Cheung, Kwok-Leung, primary, Evans, Abigail, primary, Holcombe, Chris, primary, Skene, Anthony, primary, Rea, Daniel, primary, Ahmed, Samreen, primary, Jahan, Ali, primary, Horgan, Kieran, primary, Rauchhaus, Petra, primary, Littleford, Roberta, primary, Cheung, S.Y. Amy, primary, Cullberg, Marie, primary, de Bruin, Elza C., primary, Koulai, Loumpiana, primary, Lindemann, Justin P.O., primary, Pass, Martin, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Deb, Rahul, primary, Finlay, Pauline, primary, Foxley, Andrew, primary, and Gee, Julia M.W., primary

Published
2023
Full Text
View/download PDF

23. Supplementary material from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Author

Banerji, Udai, primary, Dean, Emma J., primary, Pérez-Fidalgo, J. Alejandro, primary, Batist, Gerald, primary, Bedard, Philippe L., primary, You, Benoit, primary, Westin, Shannon N., primary, Kabos, Peter, primary, Garrett, Michelle D., primary, Tall, Mathew, primary, Ambrose, Helen, primary, Barrett, J. Carl, primary, Carr, T. Hedley, primary, Cheung, S.Y. Amy, primary, Corcoran, Claire, primary, Cullberg, Marie, primary, Davies, Barry R., primary, de Bruin, Elza C., primary, Elvin, Paul, primary, Foxley, Andrew, primary, Lawrence, Peter, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Yates, James, primary, and Schellens, Jan H.M., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 3 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 1 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure 2 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 4 from A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Author

Banerji, Udai, primary, Dean, Emma J., primary, Pérez-Fidalgo, J. Alejandro, primary, Batist, Gerald, primary, Bedard, Philippe L., primary, You, Benoit, primary, Westin, Shannon N., primary, Kabos, Peter, primary, Garrett, Michelle D., primary, Tall, Mathew, primary, Ambrose, Helen, primary, Barrett, J. Carl, primary, Carr, T. Hedley, primary, Cheung, S.Y. Amy, primary, Corcoran, Claire, primary, Cullberg, Marie, primary, Davies, Barry R., primary, de Bruin, Elza C., primary, Elvin, Paul, primary, Foxley, Andrew, primary, Lawrence, Peter, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Rugman, Paul, primary, Schiavon, Gaia, primary, Yates, James, primary, and Schellens, Jan H.M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Material from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Tamura, Kenji, primary, Oliveira, Mafalda, primary, Ciruelos, Eva M., primary, Mayer, Ingrid A., primary, Sablin, Marie-Paule, primary, Biganzoli, Laura, primary, Ambrose, Helen J., primary, Ashton, Jack, primary, Barnicle, Alan, primary, Cashell, Des D., primary, Corcoran, Claire, primary, de Bruin, Elza C., primary, Foxley, Andrew, primary, Hauser, Joana, primary, Lindemann, Justin P.O., primary, Maudsley, Rhiannon, primary, McEwen, Robert, primary, Moschetta, Michele, primary, Pass, Martin, primary, Rowlands, Vicky, primary, Schiavon, Gaia, primary, Banerji, Udai, primary, Scaltriti, Maurizio, primary, Taylor, Barry S., primary, Chandarlapaty, Sarat, primary, Baselga, José, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Table 1 from AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

Author

Chresta, Christine M., primary, Davies, Barry R., primary, Hickson, Ian, primary, Harding, Tom, primary, Cosulich, Sabina, primary, Critchlow, Susan E., primary, Vincent, John P., primary, Ellston, Rebecca, primary, Jones, Darren, primary, Sini, Patrizia, primary, James, Dominic, primary, Howard, Zoe, primary, Dudley, Phillippa, primary, Hughes, Gareth, primary, Smith, Lisa, primary, Maguire, Sharon, primary, Hummersone, Marc, primary, Malagu, Karine, primary, Menear, Keith, primary, Jenkins, Richard, primary, Jacobsen, Matt, primary, Smith, Graeme C.M., primary, Guichard, Sylvie, primary, and Pass, Martin, primary

Published
2023
Full Text
View/download PDF

30. Correction: Proliferation and AKT Activity Biomarker Analyses after Capivasertib (AZD5363) Treatment of Patients with ER+ Invasive Breast Cancer (STAKT)

Author

Robertson, John F.R., primary, Coleman, Robert E., additional, Cheung, Kwok-Leung, additional, Evans, Abigail, additional, Holcombe, Chris, additional, Skene, Anthony, additional, Rea, Daniel, additional, Ahmed, Samreen, additional, Jahan, Ali, additional, Horgan, Kieran, additional, Rauchhaus, Petra, additional, Littleford, Roberta, additional, Amy Cheung, S.Y., additional, Cullberg, Marie, additional, de Bruin, Elza C., additional, Koulai, Loumpiana, additional, Lindemann, Justin P.O., additional, Pass, Martin, additional, Rugman, Paul, additional, Schiavon, Gaia, additional, Deb, Rahul, additional, Finlay, Pauline, additional, Foxley, Andrew, additional, and Gee, Julia M.W., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results